The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

Launched by SINGAPORE NATIONAL EYE CENTRE · May 2, 2017

Keywords

ClinConnect Summary

The ATOM3 clinical trial is studying a low dose of atropine eye drops (0.01%) to see if it can help prevent or slow down myopia, which is also known as nearsightedness, in children who are at high risk. Myopia can make it difficult to see distant objects clearly, and this trial is important because it focuses on kids who already show early signs of myopia or have mild myopia. The trial is currently active but not recruiting new participants.

To be eligible for this study, children should be between the ages of 6 to 12 and have a parent who also has myopia (nearsightedness). They should have a mild level of nearsightedness themselves, with specific measurements of their vision and no serious eye conditions. Participants will receive the atropine eye drops and will be monitored to see how it affects their vision over time. This trial could lead to new ways to manage myopia in children, which is becoming more common in today’s world.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • 1. One parent with myopia (\<-3D in at least one eye)
• • 2. SE +1.00D to -1.50D
• • 3. Astigmatism \< = 1.50D
• • 4. Distance vision logMAR 0.2 or better in both eyes
• • 5. Intraocular pressure of not greater than 21 mmHg
• • 6. No allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride
• Exclusion Criteria:
• • 1. Any eye or systemic disease that affect vision or refractive error
• • 2. Conditions where topical atropine contraindicated
• • 3. Previous use of atropine or pirenzepine
• • 4. Known past/current amblyopia or strabismus